Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells

Circulation Research

Volumn 83, Issue 11, 1998, Pages 1097-1103

  Marx, Nikolaus ^a   Schönbeck, Uwe ^a   Lazar, Mitchell A ^b   Libby, Peter ^a   Plutzky, Jorge ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Gene expression; Migration; Peroxisome proliferator activated receptor gamma; Troglitazone; Vascular smooth muscle cell

Indexed keywords

15 DEOXY 12,14 PROSTAGLANDIN J2; GELATINASE B; MATRIX METALLOPROTEINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHORBOL 13 ACETATE 12 MYRISTATE; TROGLITAZONE; UNCLASSIFIED DRUG;

ARTICLE; ATHEROSCLEROSIS; CELL MIGRATION; CONCENTRATION RESPONSE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

EID: 0344333464     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.83.11.1097     Document Type: Article

References (34)

1. Galis Z, Muszynski M, Sukhova G, Simon-Morrissey E, Unemori E, Lark M, Amento E, Libby P. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix degradation. Circ Res. 1994;75:181-189.
2. Bendeck M, Zempo N, Clowes A, Galardy R, Reidy M. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res. 1994;75:539-545.
3. Galis Z, Sukhova G, Lark M, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994;94:2493-2503.
4. Brown DL, Hibbs MS, Kearney M, Loushin C, Isner JM. Identification of 92 kD gelatinase in human coronary atherosclerotic lesions. Circulation. 1995;91:2125-2131.
5. Fabunmi RP, Baker AH, Murray EJ, Booth RF, Newby AC. Divergent regulation by growth factors and cytokines of 95 kDa and 72 kDa gelatinases and tissue inhibitors or metalloproteinases-1, -2, and -3 in rabbit aortic smooth muscle cells. Biochem J. 1996;315:335-342.
6. Schönbeck U, Mach F, Sukhova G, Murphy C, Bonnefoy J-Y, Fabunmi R, Libby P. Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes. Circ Res. 1997;81: 448-454.
7. Law R, Meehan W, Xi X, Graf K, Wuthrich D, Coats W, Faxon D, Hsueh W. Troglitazone inhibits vascular smooth muscle cell growth and intimai hyperplasia. J Clin Invest. 1996;98:1897-1905.
8. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem. 1995;270:12953-12956.
9. Zhu Y, Qi C, Korenberg J, Chen X, Noya D, Rao M, Reddy J. Structural organization of mouse peroxisome proliferator-activated receptor γ (mPPARγ) gene: alternative promotor use and different splicing yield two mPPARy isoforms. Proc Natl Acad Sci U S A. 1995;92:7921-7925.
10. Schoonjans K, Peinado-Onsurbe J, Lefebvre A, Deeb S, Staels B, Auwerx J. PPARα and PPARγ activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 1996;15:5336-5348.
11. Schoonjans K, Martin G, Staels B, Auwerx J. Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr Opin Lipidol. 1997;8:159-166.
12. Fajas L, Auboeuff D, Raspe E, Schoonjans K, Lefebvre A-M, Saladin R, Najib J, Laville M, Fruchart J-C, Deeb S, Vidal-Puig A, Flier J, Briggs M, Staels B, Vidai H, Auwerx J. The organization, promotor analysis, and expression of the human PPARγ gene. J Biol Chem. 1997;272: 18779-18789.
13. 2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell. 1995;83: 813-819.
14. 2 is a ligand for the adipocyte determination factor PPAR gamma. Cell. 1995;83:803-812.
15. Marx N, Sukhova G, Murphy C, Libby P, Plutzky J. Macrophages in human atheroma contain PPARγ: differentiation-dependent PPARγ expression and reduction of MMP-9 activity through PPARγ activation in mononuclear phagocytes. Am J Pathol. 1998;153:17-23.
16. Ricote M, Huang J, Fajas L, Li A, Welch J, Najib J, Witztum JL, Auwerx J, Palinski W, Glass CK. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci U S A. 1998;95:7614-7619.
17. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 1998;391:79-82.
18. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391:82-86.
19. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 1998;93:241-252.
20. Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell. 1998;93:229-240.
21. Staels B, Koenig W, Habib A, Merval R, Lebret M, Pineda Torra I, Delerive P, Fadel A, Chinetti G, Fruchart J-C, Najib J, Maclouf J, Tedgui A. Activation of human aortic smooth muscle cells is inhibited by PPARα but not by PPARγ activators. Nature. 1998;393:790-793.
22. Reginato MJ, Krakow SL, Bailey ST, Lazar MA. Prostaglandins promote and block adipogenesis through opposing effects on peroxisome proliferator-activated receptor gamma. J Biol Chem. 1998;273: 1855-1858.
23. Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble CS, Devchand P, Wahli W, Willson TM, Lenhard JM, Lehmann JM. Fatty acids and eicosanoids regulate gene expression through direct interactions with the peroxisome proliferator-activated receptor alpha and gamma. Proc Natl Acad Sci U S A. 1997;94:4318-4323.
24. 22a. Keller H, Dreyer C, Medin J, Mahfoudi A, Ozato K, Wahli W. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc Natl Acad Sci U S A. 1993;90:2160-2164.
25. Vu-Dac N, Schoonjans K, Laine B, Fruchart J, Auwerx J, Staels B. Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element. J Biol Chem. 1994;269: 31012-31018.
26. Rentoumis A, Chatterjee V, Madison L, Datta S, Gallagher G, Degroot L, Jameson J. Negative and positive transcriptional regulation by thyroid hormone receptor isoforms. Mol Endocrinol. 1990;4:1522-1531.
27. Pfahl M. Nuclear receptor/AP-1 interaction. Endocr Rev. 1993;14: 651-658.
28. Schwarz E, Reginato M, Shao D, Krakow S, Lazar M. Retinoic acid blocks adipogenesis by inhibiting C/EBPbeta-mediated transcription. Mol Cell Biol. 1997;17:1552-1561.
29. Kamei Y, Xu L, Heinzel T, Torchia J, Kurokawa R, Gloss B, Lin S, Heyman R, Rose D, Glass C, Rosenfeld M. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell. 1996;85:403-414.
30. Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury, I: smooth muscle growth in the absence of endothelium. Lab Invest. 1983;49:327-333.
31. Cominacini L, Garbin U, Fratta-Pasini A, Campagnola M, Davoli A, Foot E, Sighieri G, Sironi A, Lo Cascio V, Ferranini E. Troglitazone reduces LDL oxidation and lowers plasma E-selectin concentrations in NIDDM patients. Diabetes. 1998;47:130-133.
32. Minamikawa J, Yamauchi M, Innoue D, Koshiyama H. Another potential use of troglitazone in non-insulin dependent diabetes mellitus. J Clin Endocrinol Metab. 1998;83:1041-1042.
33. Schwartz S, Raskin P, Fonseca V, Graveline J. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. N Engl J Med. 1998;338:861-866.
34. Inzuchi S, Maggs D, Spollet G, Page S, Rife F, Walton V, Shulman G. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes. N Engl J Med. 1998;338:867-872.